Cellply

About

Cellply is a biotechnology and deep tech company based in Bologna, Italy, founded in 2013. The company specializes in analytical tools for single-cell resolution characterization of immune cells, cancer immunotherapies, and cell-based therapies. Its mission is to accelerate research and development, process development, quality control, and clinical monitoring in the field of cell therapies. The company employs around 29-30 professionals, including engineers and biologists, and has secured over €15 million in funding. Cellply utilizes patented microfluidic technology, AI-powered image analysis, and automation to analyze immune system function and support anti-cancer drug development. Its flagship product, VivaCyte, is an end-to-end platform for single-cell potency characterization of cellular immunotherapies, capable of processing over 100 samples per run. The broader Cellply Platform offers an analytical system for testing therapies on various samples, evaluating the potency of different treatments at a single-cell level.